According to three separate studies, psilocybins medicinal and social value is extraordinary. The first study comes from the researchers at the University of Alabama at Birmingham. The research collected showed people that have taken psychedelics were 27% less likely to commit theft and 18% less likely to have committed a violent crime.
The authors wrote, “These findings are consistent with a growing body of research suggesting classic psychedelics confer enduring psychological and prosocial benefits,”
The second study was published by the Johns Hopkins University School of Medicine. They studied the psychiatric effect of the drug on cancer patients dealing with depression and anxiety.
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with [more than] 80% endorsing moderately or greater increased well-being/life satisfaction. Community observer ratings showed corresponding changes. Mystical-type psilocybin experience on session day mediated the effect of psilocybin dose on therapeutic outcomes.
The third study comes out of the NYU School Medicine and Bellevue Hospital. “29 patients with cancer-related anxiety and depression were randomly assigned and received treatment with single-dose psilocybin (0.3 mg/kg) or niacin, both in conjunction with psychotherapy.”
“psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual wellbeing, and increased quality of life. At the 6.5 month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death.”
The research is overwhelmingly irrefutable, and it is becoming more and more difficult for the federal government to justify schedule 1 drug classification for psilocybin mushrooms.